Background: High hepatitis C cure rates have been observed in registration trials with
second-generation direct-acting antivirals. Real-world data also indicate high sustained viral …

Summary Background In England, choice of hepatitis C therapy is determined by national
contracts that change with time, facilitating comparisons between different regimens …

Background & Aims Clinical trials evaluating second-generation direct-acting antiviral
agents (DAAs) have shown excellent rates of sustained virologic response (SVR) and good …

Second-generation direct-acting antivirals (DAA) have shown high sustained virologic
response (SVR) for the treatment of chronic hepatitis C in clinical trials. The objective of this …

Background/aims Direct‐acting antivirals (DAAs) are highly effective in treating chronic
hepatitis C virus (HCV)‐infected patients. The real‐world treatment outcome in Taiwanese …

The effectiveness of direct‐acting agents (DAAs) for hepatitis C treatment in limited‐resource
settings remains unclear. We estimated the pooled sustained virological response rates of …

As direct‐acting antiviral (DAA) agents become more readily available for the treatment of
chronic hepatitis C, it is important to understand real‐world treatment experiences. In order …

Background Direct acting antiviral (DAA) therapy is highly effective for hepatitis C virus
(HCV) infection, but reinfection following treatment may compromise benefits of cure. This …

BACKGROUND Regimens involving direct-acting antiviral agents (DAAs) are recommended
for the treatment of infection with hepatitis C virus (HCV) genotypes 1, 2 and 3. But real …

Background: Interferon-based treatment is not suitable for many patients with hepatitis C
virus (HCV) infection because of contraindications such as psychiatric illness, and a high …